Seladelpar

Seladelpar
Clinical data
Trade namesLivdelzi
Other namesMBX-8025; RWJ-800025
AHFS/Drugs.comLivdelzi
License data
Routes of
administration		By mouth
ATC code
  • None
Legal status
Legal status
Identifiers
  • 2-[4-[(2R)-2-ethoxy-3-[4-(trifluoromethyl)phenoxy]propyl]sulfanyl-2-methylphenoxy]acetic acid
CAS Number
PubChem CID
DrugBank
ChemSpider
UNII
KEGG
ChEMBL
CompTox Dashboard (EPA)
Chemical and physical data
FormulaC21H23F3O5S
Molar mass444.47 g·mol−1
3D model (JSmol)
  • CCO[C@H](COC1=CC=C(C=C1)C(F)(F)F)CSC2=CC(=C(C=C2)OCC(=O)O)C
  • InChI=1S/C21H23F3O5S/c1-3-27-17(11-28-16-6-4-15(5-7-16)21(22,23)24)13-30-18-8-9-19(14(2)10-18)29-12-20(25)26/h4-10,17H,3,11-13H2,1-2H3,(H,25,26)/t17-/m1/s1
  • Key:JWHYSEDOYMYMNM-QGZVFWFLSA-N

Seladelpar, sold under the brand name Livdelzi, is a medication used for the treatment of primary biliary cholangitis.[1] It is used as the lysine dihydrate salt.[1] It is a PPARδ receptor agonist.[1][2][3] The compound was licensed from Janssen Pharmaceutica NV.[4]

Seladelpar was approved for medical use in the United States in August 2024.[1][5]

Medical uses

[edit]

Seladelpar is indicated for the treatment of primary biliary cholangitis in combination with ursodeoxycholic acid in adults who have an inadequate response to ursodeoxycholic acid, or as monotherapy in people unable to tolerate ursodeoxycholic acid.[1]

Clinically, Seladelpar reduces pruritus and IL-31 in patients with primary biliary cholangitis.[6]

References

[edit]
  1. ^ a b c d e f "Livdelzi- seladelpar lysine capsule". DailyMed. 14 August 2024. Retrieved 5 September 2024.
  2. ^ Billin AN (October 2008). "PPAR-beta/delta agonists for Type 2 diabetes and dyslipidemia: an adopted orphan still looking for a home". Expert Opinion on Investigational Drugs. 17 (10): 1465–1471. doi:10.1517/13543784.17.10.1465. PMID 18808307. S2CID 86564263.
  3. ^ Bays HE, Schwartz S, Littlejohn T, Kerzner B, Krauss RM, Karpf DB, et al. (September 2011). "MBX-8025, a novel peroxisome proliferator receptor-delta agonist: lipid and other metabolic effects in dyslipidemic overweight patients treated with and without atorvastatin". The Journal of Clinical Endocrinology and Metabolism. 96 (9): 2889–2897. doi:10.1210/jc.2011-1061. PMID 21752880.
  4. ^ "Targeting Mixed Dyslipidemia and Metabolic Syndrome". Metabolex, Inc. 2005. Archived from the original on 17 October 2006.
  5. ^ "Gilead's Livdelzi (Seladelpar) Granted Accelerated Approval for Primary Biliary Cholangitis by U.S. FDA" (Press release). Gilead. 14 August 2024. Retrieved 15 August 2024 – via Business Wire.
  6. ^ Kremer AE, Mayo MJ, Hirschfield GM, Levy C, Bowlus CL, Jones DE, et al. (July 2024). "Seladelpar treatment reduces IL-31 and pruritus in patients with primary biliary cholangitis". Hepatology. 80 (1): 27–37. doi:10.1097/HEP.0000000000000728. PMC 11191048. PMID 38117036.


Stub icon

This drug article relating to the gastrointestinal system is a stub. You can help Wikipedia by expanding it.

Retrieved from "https://en.wikipedia.org/w/index.php?title=Seladelpar&oldid=1249659970"